Safety Trolls?: Generic Firms Seek To Invalidate Xyrem REMS Patent Via PTO
This article was originally published in The Pink Sheet Daily
Executive Summary
In a first by drug makers seeking covered business method patent review, Amneal, Par and Roxane petition PTO appeal board to cancel patent claims covering distribution of Jazz’s Xyrem.
You may also be interested in...
FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.